Here, BCR-ABL1 kinase is constitutively active in the majority of CML patients and tyrosine kinase inhibitors, targeting the oncogenic product BCR-ABL, are an effective treatment strategy in CML patients [146]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.